会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Solid depot drug form
    • 固体贮库药物形式
    • US5552159A
    • 1996-09-03
    • US125133
    • 1993-09-23
    • Winfried MuellerReinhard SpenglerSven GrabowskiAxel Sanner
    • Winfried MuellerReinhard SpenglerSven GrabowskiAxel Sanner
    • A61K9/20A61K9/22
    • A61K9/2095A61K9/2027A61K9/2054
    • A solid depot drug form produced by melt extrusion at from 50.degree. to 200.degree. C. and continuous shaping of a mixture of from 0.1 to 70% by weight, based on the finished depot form, of a pharmaceutical active ingredient with a polymer melt of the following composition:a) at least 6% by weight, based on the complete depot form, of at least one water-insoluble poly(meth) acrylate with a glass transition temperature Tg in the range from -60.degree. to 180.degree. C.,b) a water-soluble hydroxyalkylcellulose or hydroxy-alkylmethylcellulose with 2 or 3 carbons in the hydroxyalkyl, or an N-vinylpyrrolidone polymer with from 0 to 50% by weight of vinyl acetate or a mixture of the two in the ratio a):b) =5:95 to 95:5, andc) 0-30% by weight, based on the finished depot form, of one or more conventional pharmaceutical auxiliaries.
    • 一种固体贮库药物形式,其通过在50℃至200℃的熔融挤出而制备,并且基于最终的贮库形式连续成型0.1至70重量%的混合物,药物活性成分与聚合物熔体 以下组合物:a)至少6重量%,基于完整的储存形式,至少一种水不溶性聚(甲基)丙烯酸酯的玻璃化转变温度Tg在-60℃至180℃的范围内。 ,b)在羟烷基中具有2或3个碳原子的水溶性羟烷基纤维素或羟基烷基甲基纤维素,或0-50重量%乙酸乙烯酯的N-乙烯基吡咯烷酮聚合物或两者的混合物,其比例a): b)= 5:95至95:5,和c)基于成品仓库形式的一种或多种常规药物助剂的0-30重量%。